Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 17;2(8):100359.
doi: 10.1016/j.xcrm.2021.100359. Epub 2021 Jul 9.

Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose

Andres H Rossi  1 , Diego S Ojeda  1 , Augusto Varese  2 , Lautaro Sanchez  1 , Maria M Gonzalez Lopez Ledesma  1 , Ignacio Mazzitelli  2 , Anabel Alvarez Juliá  1 , Santiago Oviedo Rouco  1 , Horacio M Pallarés  1 , Guadalupe S Costa Navarro  1 , Natali B Rasetto  1 , Corina I Garcia  1 , Shirley D Wenker  1 , Lila Y Ramis  1 , Magalí G Bialer  1 , Maria Jose de Leone  1 , C Esteban Hernando  1 , Santiago Sosa  1 , Luciana Bianchimano  1 , Antonella S Rios  1 , Maria Soledad Treffinger Cienfuegos  1 , Julio J Caramelo  1 , Yesica Longueira  2   3 , Natalia Laufer  2   3 , Diego E Alvarez  4 , Jorge Carradori  5 , Dariana Pedrozza  6 , Alejandra Rima  7 , Cecilia Echegoyen  8 , Regina Ercole  9 , Paula Gelpi  10 , Susana Marchetti  11 , Martín Zubieta  12 , Guillermo Docena  13 , Nicolas Kreplak  14 , Marcelo Yanovsky  1 , Jorge Geffner  2 , Marina Pifano  14 , Andrea V Gamarnik  1
Affiliations

Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose

Andres H Rossi et al. Cell Rep Med. .

Abstract

Massive vaccination offers great promise for halting the global COVID-19 pandemic. However, the limited supply and uneven vaccine distribution create an urgent need to optimize vaccination strategies. We evaluate SARS-CoV-2-specific antibody responses after Sputnik V vaccination of healthcare workers in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses in a cohort of naive or previously infected volunteers. By 21 days after receiving the first dose of the vaccine, 94% of naive participants develop spike-specific IgG antibodies. A single Sputnik V dose elicits higher antibody levels and virus-neutralizing capacity in previously infected individuals than in naive ones receiving the full two-dose schedule. The high seroconversion rate after a single dose in naive participants suggests a benefit of delaying administration of the second dose to increase the number of people vaccinated. The data presented provide information for guiding public health decisions in light of the current global health emergency.

Keywords: COVID-19; COVIDAR IgG; SARS-CoV-2 vaccination; Sputnik V; WHO SARS-CoV-2 antibody International Standard; neutralizing antibodies; seroconversion.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

None
Graphical abstract
Figure 1
Figure 1
Immune response to SARS-CoV-2 Sputnik V vaccine (A) Quantitative SARS-CoV-2 spike antibody titers for 288 participants, with or without prior infection (indicated as seropositive or seronegative at baseline, respectively). Measurements were performed before vaccination (baseline), 21 days after the first dose, and 21 days after the second dose. Geometric means with 95% confidence intervals are shown. The Mann-Whitney U test was used to compare at various time points antibody titers. Statistical significance is shown with the following notations: ∗∗∗∗p < 0.0001; ns, not significant. (B) Seroconvertion after one dose in participants older or younger than 60 years. (C) Quantification of antibody levels by WHO International Standard.
Figure 2
Figure 2
Neutralizing capacity with and without prior SARS-CoV-2 infection after one and two doses of Sputnik V vaccine Neutralizing titers were measured by 80% inhibition for the pseudotyped virus (CoV2pp GFP) in 232 participants. For WT SARS-CoV-2, neutralization titer was defined as the highest serum dilution without any cytopathic effect on the monolayer. Titers at baseline and 21 days after one or two doses are shown. Left and right panels display data from individuals who were seronegative or seropositive at baseline, as indicated at top, respectively. Geometric means with 95% confidence intervals are shown in the dashed lines. The Mann-Whitney U test was used to compare at various time points antibody titers. Statistical significance is shown with the following notations: ∗∗∗∗p < 0.0001; ns, not significant.
See this image and copyright information in PMC

References

    1. Logunov D.Y., Dolzhikova I.V., Zubkova O.V., Tukhvatulin A.I., Shcheblyakov D.V., Dzharullaeva A.S., Grousova D.M., Erokhova A.S., Kovyrshina A.V., Botikov A.G. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396:887–897. - PMC - PubMed
    1. Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., Kovyrshina A.V., Lubenets N.L., Grousova D.M., Erokhova A.S., Gam-COVID-Vac Vaccine Trial Group Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671–681. - PMC - PubMed
    1. Hung I.F.N., Poland G.A. Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster. Lancet. 2021;397:854–855. - PMC - PubMed
    1. Krammer F., Srivastava K., Alshammary H., Amoako A.A., Awawda M.H., Beach K.F., Bermúdez-González M.C., Bielak D.A., Carreño J.M., Chernet R.L. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N. Engl. J. Med. N. Engl. J. Med. 2021;384:1372–1374. - PMC - PubMed
    1. Ebinger J.E., Fert-Bober J., Printsev I., Wu M., Sun N., Prostko J.C., Frias E.C., Stewart J.L., Van Eyk J.E., Braun J.G. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat. Med. 2021;27:981–984. - PMC - PubMed

Publication types

MeSH terms